Astex Pharmaceuticals to Present at Lazard Healthcare Conference on November 16th

DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Martin Buckland, D.Phil., chief business officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16th in New York.

The Company's presentation will begin at 10:00 a.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's website, www.astx.com. The webcast will be archived for 30 days.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.



CONTACT:

Astex Pharmaceuticals, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Marketing
[email protected]
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]
or
The Trout Group
Alan Roemer, 646-378-2945
Managing Director
[email protected]
or
College Hill
Melanie Toyne-Sewell, +44 20 7866 7866 (Europe)
Rebecca Skye Dietrich, 857-241-0795 (US)
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.